Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 4/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.55 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.55 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.50 |
| ▸ | APEX1 | P27695 | 1/20 | 0.48 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.46 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 4/20 | 0.44 |
| ▸ | PPARD | Q03181 | 4/20 | 0.44 |
| ▸ | PPARA | Q07869 | 4/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL511473 | 0.97 | TSHR (0.60) | LMNATSHRNFKB1PMP22SLC22A6 | |
| SCHEMBL15302954 | 0.97 | TSHR (0.60) | LMNATSHRNFKB1PMP22SLC22A6 | |
| SCHEMBL503550 | 0.97 | TSHR (0.60) | LMNATSHRNFKB1PMP22SLC22A6 | |
| SCHEMBL719958 | 0.97 | TSHR (0.60) | LMNATSHRNFKB1PMP22SLC22A6 | |
| SCHEMBL7609467 | 0.97 | TSHR (0.60) | LMNATSHRNFKB1PMP22SLC22A6 | |
| SCHEMBL8576746 | 0.97 | TSHR (0.60) | LMNATSHRNFKB1PMP22SLC22A6 | |
| SCHEMBL8573097 | 0.97 | TSHR (0.60) | LMNATSHRNFKB1PMP22SLC22A6 | |
| SCHEMBL16778332 | 0.97 | TSHR (0.60) | LMNATSHRNFKB1PMP22SLC22A6 | |
| SCHEMBL8574509 | 0.97 | TSHR (0.60) | LMNATSHRNFKB1PMP22SLC22A6 | |
| SCHEMBL8572239 | 0.97 | TSHR (0.60) | LMNATSHRNFKB1PMP22SLC22A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10947123-B2 | Synthetic caustic composition | FLUID ENERGY GROUP LTD. (CA) | 2021-03-16 | — | — | US | claimed |
| US-20190144741-A1 | NOVEL SYNTHETIC CAUSTIC COMPOSITION | HSBC BANK MIDDLE EAST LIMITED (AE) | 2019-05-16 | — | — | US | claimed |
| CN-101547895-B | Photoactive compounds | AZ ELECTRONIC MATERIALS USA | 2014-12-03 | — | — | CN | claimed |
| CN-101547895-A | Photoactive compounds | AZ ELECTRONIC MATERIALS USA (US) | 2009-09-30 | — | — | CN | claimed |
| CN-101547913-A | Photoactive compounds | AZ ELECTRONIC MATERIALS USA (US) | 2009-09-30 | — | — | CN | claimed |
| CN-101218225-A | Photoactive compounds | AZ ELECTRONIC MATERIALS USA (US) | 2008-07-09 | — | — | CN | claimed |
| US-20240217983-A1 | GPR119 AGONISTS | KALLYOPE, INC. | 2024-07-04 | — | — | US | disclosed |
| US-20240165139-A1 | GALACTOPYRANOSYL-CYCLOHEXYL DERIVATIVES AS E-SELECTIN ANTAGONISTS | GLYCOMIMETICS, INC. (US) | 2024-05-23 | — | — | US | disclosed |
| EP-4320129-A1 | GPR119 AGONISTS | Kallyope, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| US-11878026-B2 | Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists | GLYCOMIMETICS, INC. (US) | 2024-01-23 | — | — | US | disclosed |
| US-20220372398-A1 | High Alkaline High Foam Cleaners with Controlled Foam Life | HSBC BANK MIDDLE EAST LIMITED (AE) | 2022-11-24 | — | — | US | disclosed |
| WO-2022236397-A1 | HIGH ALKALINE HIGH FOAM CLEANERS WITH CONTROLLED FOAM LIFE | FLUID ENERGY GROUP LTD. (CA) | 2022-11-17 | — | — | WO | disclosed |
| WO-2022216709-A1 | GPR119 AGONISTS | KALLYOPE, INC. (US) | 2022-10-13 | — | — | WO | disclosed |
| CN-101218225-A | Photoactive compounds | AZ ELECTRONIC MATERIALS USA (US) | 2008-07-09 | — | — | CN | disclosed |
| CN-1509187-A | Cytotoxic CD44 antibody immunoconjugates | ���ָ��Ӣ��ķ�������Ϲ�˾ | 2004-06-30 | — | — | CN | disclosed |
| EP-0062430-B1 | PROCESS FOR THE PREPARATION OF (OMEGA-FLUOROSULFONYL) HALOALIPHATIC CARBOXYLIC ACID FLUORIDES | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1986-11-12 | — | — | EP | disclosed |
| US-4466881-A | ELECROLYTIC FLUORINATION | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1984-08-21 | — | — | US | disclosed |
| US-4425199-A | FLUORINATION, ELECTROLYSIS | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1984-01-10 | — | — | US | disclosed |
| EP-0062430-A1 | Process for the preparation of (omega-fluorosulfonyl) haloaliphatic carboxylic acid fluorides | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1982-10-13 | — | — | EP | disclosed |
| US-4029744-A | Process for removing the salt of a weak acid and a weak base from solution | EXXON RESEARCH AND ENGINEERING COMPANY (US) | 1977-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240217983-A1 | GPR119 AGONISTS | GPR119, GLP1R, GCGR | LMNA 4659/4885TSHR 472/4885NFKB1 3559/4885 |
| US-11878026-B2 | Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists | SELE, SELPLG, SELP | LMNA 1122/4885TSHR 1766/4885NFKB1 1720/4885 |
| US-20240165139-A1 | GALACTOPYRANOSYL-CYCLOHEXYL DERIVATIVES AS E-SELECTIN ANTAGONISTS | SELE, SELPLG, SELP | LMNA 1122/4885TSHR 1766/4885NFKB1 1720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.